Herbal Formula Huangqi Guizhi Wuwu Decoction Attenuates Paclitaxel-related Neurotoxicity via Inhibition of Inflammation and Oxidative Stress

Zhangming Lv  
Nanjing University of Chinese Medicine

Jiayun Shen  
Nanjing University of Chinese Medicine

Xuejiao Gao  
Nanjing University of Chinese Medicine

Yonglan Ruan  
Nanjing University of Chinese Medicine

Jinying Ling  
Nanjing University of Chinese Medicine

Rongwei Sun  
Nanjing University of Chinese Medicine

Jingya Dai  
Nanjing University of Chinese Medicine

Haizhen Fan  
Nanjing University of Chinese Medicine

Xiaolan Cheng  
Nanjing University of Chinese Medicine

Peng Cao  
Nanjing University of Chinese Medicine  cao_peng@njucm.edu.cn

Research

Keywords: Huangqi Guizhi Wuwu decoction, paclitaxel, peripheral neuropathy, network pharmacology, inflammation, oxidative stress

DOI: https://doi.org/10.21203/rs.3.rs-544931/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Paclitaxel-induced peripheral neuropathy (PIPN) is a challenging clinical problem during chemotherapy. Our previous work found that herbal formula Huangqi Guizhi Wuwu decoction (HGWD) could reduce oxaliplatin-induced neurotoxicity. However, its effect on PIPN remains unknown. In this study, we aim to investigate the therapeutic effect and the underlying mechanisms of HGWD against PIPN with pharmacological and network pharmacology.

Methods: Male Wistar rats were used to establish an animal model of PIPN and treated with different doses of HGWD for 3 weeks. Mechanical allodynia, thermal hyperalgesia and body weight were measured to evaluate the therapeutic effect of HGWD on PIPN rats. On the day of the sacrifice, blood, DRGs, sciatic nerve, and hind-paw intra-plantar skins were collected to assess neuroprotective effect of HGWD on PIPN. Next, network pharmacology was performed to decipher the potential active components and molecular mechanisms of HGWD, as were further verified by western blotting analyses in PIPN rats. Finally, the effect of HGWD on the chemotherapeutic activity of paclitaxel was evaluated in vitro and in vivo.

Results: In rats with PIPN, HGWD reversed mechanical allodynia, thermal hyperalgesia, and ameliorated neuronal damage. Moreover, HGWD significantly increased the level of nerve growth factor, dramatically reduced IL-1β, IL-6, TNF-α levels and oxidative stress. Network pharmacology analysis revealed 30 active ingredients in HGWD and 158 candidate targets. Integrated pathway analysis identified PI3K/Akt and toll-like receptor as two main pathways responsible for the neuroprotective effect of HGWD. Further experimental validation demonstrated that HGWD expectedly inhibited the protein expression of TLR4, MyD88, IKKα, and p-NF-κB, and promoted PI3K, p-Akt, Nrf2, and HO-1 level in dorsal root ganglia. Last but not least, HGWD did not interfere with the antitumor activity of paclitaxel both in in vitro and in vivo models.

Conclusion: These combined data showed that HGWD could inhibit paclitaxel-evoked inflammatory and oxidative responses in peripheral nervous system via TLR4/NF-κB and PI3K/Akt-Nrf2 pathways involvement. The neuroprotective property of HGWD on PIPN provides fundamental support to the potential application of HGWD for counteracting the side effects of paclitaxel during chemotherapy.

Background

Chemotherapy remains a widely used and important treatment for cancer. However, nearly 60% of cancer survivors receiving chemotherapy would experience serious chemotherapy-induced peripheral neuropathy (CIPN), characterized with pain, tingling, and numbness in the hands and/or feet [1]. To date, no definite therapeutic strategy is available for CIPN prevention or management [2–5], making it an urgent need to discover effective pharmacological agents against CIPN.

Paclitaxel (PTX) is a well-known anticancer agent because of its high effectiveness against solid tumours. Since its favourable curative effect, PTX could result in severe peripheral neuropathy, affecting
up to 50% of cancer patients [2]. PTX-induced peripheral neuropathy (PIPN) often requires a reduction in PTX dosage or even discontinuation of chemotherapy, seriously impairing the survival of cancer patients. Nonetheless, the unified mechanism of PIPN have not been fully elucidated thus far. According to recent research, PIPN may involve the loss of intra-epidermal nerve fibres (IENFs), mitochondrial damage, activation of transient receptor potential channel (TRP), and mitogen-activated protein kinase (MAPK). Oxidative stress and inflammation have also played a pivotal role in the development of a PIPN [6, 7]. Increased oxidative stress in peripheral sensory neurons can induce spontaneous discharge of neurons, and cause neuronal sensitisation and hyperalgesic responses [8]. Antioxidants, such as alphalipoic acid, have shown promising effects against CIPN via Nrf2 activation and subsequent oxidative stress inhibition [9]. Additionally, inflammation has been proven to be common in PIPN. Toll-like receptor 4/NF-κB (p65) signalling promotes the production of pro-inflammatory factors, which can damage neuron, suppress synaptic transmission, and enhance neuron response to noxious stimuli [10]. Furthermore, inflammation can activate multiple pathways, such as oxidative stress, protein kinase C, MAPK, and TRP, thereby inducing neuropathic pain. Direct inhibition of the TLR4/NF-κB pathway reduces reactive oxygen species (ROS) production and attenuates chemotherapy-induced neurotoxicity [11]. Despite advances in the mechanisms, PIPN management is still challenging, prompting researchers to seek for alternative treatment options.

Huangqi Guizhi Wuwu decoction (HGWD) is an herbal formula recorded in the “Golden Chamber”, comprising five crude drugs (Astragali Radix, Cinnamomi Ramulus, Paeoniae Radix Alba, Zingiberis Rhizoma Recens, and Jujubae Fructus). This prescription has long been used to control pain and numbness in stroke sequelae, peripheral nerve injury, and other diseases. Recent studies and our work suggest that HGWD is therapeutically effective for diabetic and oxaliplatin-induced peripheral neuropathy [12, 13]. HGWD improved neurological function, increased blood circulation and alleviated oxaliplatin-induced mechanical and cold hypersensitivity, suggesting that HGWD may offer potential opportunities to CIPN treatment. However, the effect and underlying mechanisms of HGWD against PIPN remains unknown, thus requiring further study. In this study, we integrated pharmacological evaluation and network pharmacology to decipher the efficacy and molecular mechanism of HGWD in PIPN treatment. The research framework of this study is shown in Fig. 1.

Methods

Animals

Thirty-two male Wistar rats (200 ± 30 g) were kept in a 12-h light/dark cycle with ad libitum access to water and food. The current protocol was approved by the Animal Care and Use Committee of Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine. All experimental procedures were conducted strictly in accordance with the Guide for Care and Use of Laboratory Animals.

Drugs and chemicals
PTX was purchased from Shanghai Tauto Biotech Co., Ltd. (Shanghai, China). Crude drugs, including Astragali Radix (AR), Cinnamomi Ramulus (CR), Paeonia Radix Alba (PRA), Jujubae Fructus (JF), and Zingiberis Rhizoma (ZR) were provided by Jiangsu Hospital of Integrated Traditional Chinese and Western Medicine, and authenticated based on the instructions recorded in the Chinese Pharmacopoeia (2015 edition). The voucher specimens were deposited in Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine.

**HGWD preparation**

HGWD was prepared in the following procedure: AR (140 g), CR (70 g), PRA (70 g), JF (70 g), and ZR (70 g) were immersed in distilled water (10 times the total weight) for 0.5 h and then gently refluxed two times, each time for 1 h. The two liquid extracts were combined and concentrated to 2 g/ml under reduced pressure and then stored at -80°C before use.

**Experimental design and treatment protocol**

A schematic of the experimental design is shown in Fig. 2a. Rats were randomly divided into four groups (n = 8). PTX (2 mg/kg, prepared in cremophor EL/ethanol at a ratio of 1:1) was injected intraperitoneally (i.p.) for four alternate days (days 1, 3, 5, and 7) to induce PIPN, as described previously [13]. HGWD 10 or 20 g/kg was administered orally once a day for 3 weeks from the first dose of PTX injection (1 h prior to each PTX injection, if coinciding with chemotherapy treatment). Behavioural tests were performed before and on days 6, 8, 11, 14, and 21 after the first PTX withdrawal. Blood and tissues were collected within 24 h after the final dose.

**Mechanical allodynia (von Frey test)**

Mechanical allodynia was evaluated using von Frey hair unit (IITC, Life Sciences, USA) according to a previously reported method [13]. Stimuli were applied to the hind paw of rats, and the minimum force required to elicit a clear paw withdrawal or shaking was recorded. Measurements were repeated three times at 5-min intervals, and the mean value was calculated.

**Thermal hyperalgesia (hot-plate test)**

Thermal hyperalgesia was assessed by hot plate at 52°C. The latency to jump or hind-paw lick was recorded. A cut-off time of 30 s was applied to avoid tissue damage.

**Histological analysis of dorsal root ganglia (DRG) and sciatic nerve tissue**

The dissected lumbar 4–6 (L4-6) DRG was fixed in 10% formalin solution, embedded in paraffin, and then sliced into 4–5 µm-thick sections. The sections were then stained with Nissl staining solution and examined microscopically. Sciatic nerve samples were harvested, fixed in 4% glutaraldehyde, and post-fixed in 1% osmic acid at 25°C for 2 h. Samples were then dehydrated with graded ethanol series and embedded in Epon 812. Ultrathin sections (80 nm) were prepared, double-stained with uranium acetate
and lead citrate, and then observed with an HT7700 transmission electron microscope (Hitachi, Tokyo, Japan).

**Quantification of IENF density**

For quantification of IENFs, hind-paw intra-plantar skins of rats were collected for immunohistochemical studies. The antibodies used were anti-protein gene product 9.5 (PGP9.5) primary Ab (ab108986, 1:200; Abcam, Cambridge, MA, USA) and Cy3-conjugated goat anti-rabbit IgG (ab6939, 1:300; Abcam). PGP9.5-positive IENFs were counted and expressed as the numbers of fibres/length of epidermis (IENFs/mm). The scorer was completely blinded to the experimental setup.

**Measurement of nerve growth factor (NGF) and oxidative stress markers**

Serum levels of NGF and markers of oxidative stress, such as superoxide dismutase (SOD), malondialdehyde (MDA), and 8-isoprostanate F2α, were measured. MDA and SOD levels were examined by colorimetric kits (Beyotime Biotechnology Co.Ltd, Shanghai, China). NGF and 8-isoprostanate F2α levels were measured using a rat beta-NGF ELISA Kit (Invitrogen, Grand Island, NY, USA) and 8-iso-PGF2α ELISA kit (Enzo Life Sciences, New York, USA), respectively.

**Construction of the chemical component database and screening of active compounds with its targets**

All chemical ingredients in HGWD were collected from the TCMSP and TCMID databases. The TCMSP database is a systematic pharmacology platform that reveals the mechanisms of Tradition Chinese Medicine by identifying a drug-target network, covering pharmacokinetic properties including absorption, distribution, metabolism, and excretion (ADME). In the present study, components with oral bioavailability (OB) ≥ 30%, drug likeness (DL) ≥ 0.18, and drug half-life (HL) ≥ 4 were selected as active ingredients possessing biological activity for further study. The TCMID database was applied to replenish HGWD ingredients according to target proteins that were not recorded in the TCMSP database. Next, to reveal the pharmacological mechanism of the active ingredients of HGWD, the potential targets of the candidate active compounds were predicted using the QSAR model in TargetNet. The target information collected from TCMSP, TCMID, and DrugBank databases and literatures were integrated to supplement the target database.

Construction of “HGWD-PIPN” common targets database

The main targets of PIPN-related diseases were obtained from the following databases: OMIM, GeneCards, NCBI-gene, and DisGENET. In this study, “paclitaxel-induced peripheral neuropathy” was used as the main keyword to screen disease-related targets in the above bioinformatics websites. Next, we mapped the prediction targets of the HGWD with PIPN-related disease targets. Both the PIPN-related targets and HGWD-related targets obtained were imported to draw a Venn diagram, and the overlapping
part showed the common targets of diseases and compounds. In addition, the common targets network was established and inspected using the Cytoscape 3.7.2 software.

Gene Ontology (GO), Kyoto Encyclopaedia of Genes and Genomes (KEGG), and target proteins distribution enrichment analyses

GO and KEGG pathway enrichment analyses were carried out using the KOBAS website. Enrichment analysis for cell and tissue distribution of the target proteins of HGWD was conducted on the Metascape website. To elucidate whether HGWD exerts neuroprotective effect in chemotherapy, we subjected the candidate targets to enrichment analysis of biological processes, cellular components, molecular functions, and signalling pathways, with \( P\)-value < 0.05 considered as statistically significant. The results were mainly visualised using the ggplot2 package in R 3.6.0. Information of Public databases and its website involved in the study are listed in Supplementary Table S1.

Network construction

Protein-protein interaction (PPI) predictions were used to predict the outcome of pairs or groups of protein interactions. In this study, PPI network was generated by importing the common targets into the String database, with the species restricted to “Homo sapiens” and the highest confidence core > 0.9. Finally, the obtained results were exported in the TSV format and imported into the Cytoscape software for visualisation. To analyse and visualise the relationship between effective active compounds, targets, and pathways, the compound-target (C-T) network and target-pathway (T-P) network were established by Cytoscape 3.7.2 software.

Western blotting

DRG tissues were harvested, washed, homogenised, and extracted using RIPA lysis buffer (Beyotime Biotechnology Co., Ltd.) containing protease inhibitor. Protein concentrations of lysates were measured by the bicinchoninic acid method (Beyotime Biotechnology Co., Ltd.). Protein samples were electrophoresed in a 10% SDS-PAGE gel and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% non-fat milk and incubated with the following primary antibodies overnight at 4°C: TLR4 (1:1000; Affinity Biosciences, Ltd., Cincinnati, OH, USA); MyD88, Keap1 (1:1000; Cell Signalling Technology, USA); NF-κB p65, p-NF-κB (1:1000; Absin Biotechnology Co., Ltd); PI3K, Akt, phospho-Akt(p-Akt) (1:1000; from Cell Signaling Technology, USA); Nrf2 (1:1000; Abcam); HO-1(1:1000, ABclonal Biotechnology Co., Ltd); and β-tubulin (1:3000; Affinity Biosciences, Ltd., Cincinnati, OH, USA). Afterwards, the membranes were washed with PBST, incubated with HRP-conjugated secondary antibodies (Affinity Biosciences, Ltd.), and visualised by enhanced chemiluminescence (Beyotime Biotechnology Co. Ltd.). The results were quantified using the NIH ImageJ software.

Inflammatory factors measurement

The serum levels of inflammatory cytokines, including interleukin (IL)-1β, IL-6, tumour necrosis factor-α (TNF-α), and IL-10 were tested using ELISA kits (Multi Sciences (Lianke) Biotech Co., Ltd., Hangzhou,
China). IL-1β, IL-6, TNF-α, and IL-10 mRNA in DRG tissue was measured by real-time polymerase chain reaction (RT-PCR). The gene-specific primers for rat IL-1β, IL-6, TNF-α, and IL-10 are listed in Supplementary Table S2.

**MTT assay**

Cancer cell lines, including MDA-MB-231 and CFPAC-1 cells, were purchased from the Bank of Cell, Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were maintained in DMEM (MDA-MB-231 cells) or IMEM (CFPAC-1 cells) plus 10% foetal bovine serum at 37°C in 5% CO₂.

The effect of HGWD on the tumour cell-killing ability of PTX was evaluated via an enzymatic MTT assay.

**Tumour xenograft model**

CFPAC-1 cells (4× 10⁶) were injected subcutaneously into the right flank of nude BALB/c mice (aged 3–4 weeks). When the tumours had grown to approximately 150–300 mm³, the mice were randomised into three groups (n = 7 per group): vehicle (normal saline), PTX (10 mg/kg in normal saline, i.p., q.d (days 1, 3, and 5)), and PTX (10 mg/kg) combined HGWD (30 g/kg, i.g., q.d (days 1–22)). Tumour size was measured every 3 days and calculated according to the following formula: tumour volume = length × width²/2. At the end of the experiment, the mice were sacrificed, and tumour xenografts were excised and weighed.

**Statistical analysis**

The difference between two different groups was analysed via unpaired Student’s *t*-test using the GraphPad Prism 8 software. A one-way analysis of variance (ANOVA) followed by Bonferroni analysis was used for *in vivo* comparisons among multiple groups. *P* < 0.05 was regarded as statistically significant.

**Results**

**HGWD alleviates both mechanical alldynia and heat hyperalgesia in a rat model of PIPN**

To examine the effect of HGWD on PIPN, we established a rat model of PIPN according to reported protocols [14]. A cumulative dose of 8 mg/kg PTX injection (4 × 2 mg/kg, 2 days apart, i.p.) robustly and persistently reduced hind-paw withdrawal threshold in rats (the PIPN group), compared with the vehicle (Fig. 2b, *P* < 0.01). PTX-induced mechanical alldynia was inhibited by HGWD administration. At day 14, paw-withdrawal threshold in the PIPN group was 26.7 ± 7.9 g, whereas that in HGWD (20 g/kg)-treated rats increased to 38.0 ± 4.6 g (Fig. 2b, *P* < 0.01). In rats receiving the vehicle, the threshold of withdrawal responses remained basically unchanged during the experimental period. Next, we measured the heat thermal nociceptive sensitivity of rats. The results showed that the baseline paw-withdrawal thermal latency was approximately 14.5 ± 0.3 s in each group before the treatment onset (Fig. 2c). No significant changes in paw-withdrawal latency were detected in rats receiving the vehicle. In contrast, PTX
significantly decreased the heat thermal nociceptive threshold (from 14.8 to 6.3 s) at day 8 \((P< 0.001)\). HGWD produced persistent relief of thermal sensitivity induced by PTX (Fig. 2c). However, HGWD administration could not reverse the loss of body weight after PTX treatment (Fig. 2d). These data indicated that HGWD could effectively counteract PTX-induced sensory disturbances.

**HGWD attenuates PTX-induced histological changes in DRG and sciatic nerves**

Next, we determined whether functional changes in peripheral neurons following PTX treatment were accompanied by structural alterations in peripheral nervous tissue. Histological examination of DRG revealed that the cytoplasm of neurons and satellite cells appeared normal in all experimental groups. Compared with those in vehicle group, DRG neurons in PTX-treated rats exhibited increased incidence of multinucleolate cell bodies (Fig. 2e arrowheads) and eccentric nucleoli (Fig. 2e red arrow). In HGWD-treated groups, the percentages of multinucleated nuclei and nucleolar segregation were drastically reduced compared with those in rats treated with PTX alone (Fig. 2e).

Electron microscopic examination of sciatic nerves showed the characteristic appearance of ultrastructural damage after PTX treatment. As shown in Fig. 3a & b, PTX clearly induced axonal swelling, altered myelination, and the loosening and breakdown of myelin sheath in sciatic nerves. Moreover, PTX caused swollen and vacuolated mitochondria in the axon (Fig. 3c, red arrow). G-ratio, a key measure of myelination integrity, was significantly lower in both the large (axon diameter > 5 µm) and small (axon diameter < 5 µm) fibres of sciatic nerves in the PIPN group (0.60 ± 0.05; 0.56 ± 0.09) than in the vehicle group (0.66 ± 0.08; 0.7 ± 0.04) (Fig. 3d). HGWD significantly rescued PTX-induced neurotoxic effects in sciatic nerve, including axonal degeneration and myelin damage.

**HGWD protects against PTX-induced IENF loss and reduction of NGF levels**

IENFs, projecting from the DRG or trigeminal nerve, are regarded to be responsible for sensation and noxious impulse transmission. As an early sign of PIPN, IENF loss in the plantar surface of the hind paws is associated with hypersensitivity. To explore whether HGWD alleviate PTX-induced IENF loss, the density of IENFs in the hind paws of rats was analysed with neuronal marker PGP9.5. As shown in Fig. 4a & b, PTX injection significantly reduced the density of nerve fibres entering the epidermis, compared with that in vehicle-treated rats. After HGWD administration, PTX-induced IENF retraction was significantly suppressed.

NGF, a nerve growth-regulating factor secreted mainly by neurons or glial cells, is correlated with the occurrence and severity of PIPN. Decreased NGF expression and transport have been well illustrated in the development of CIPN [15]. As illustrated in Fig. 4c, serum NGF level was remarkably reduced after PTX treatment compared with that after vehicle treatment (171.7 ± 20.5 pg/ml versus 285.1 ± 51.66 pg/ml, respectively; \(P< 0.01\)). In HGWD (20 g/kg)-treated group, the reduction was considerably lower (272.1 ± 39.1 pg/ml; \(P< 0.05\)) than that in the PIPN model group, showing no significant difference from that in
the vehicle group \((P > 0.05)\). These results suggest that HGWD can increase serum NGF levels and may promote neuron repair.

**HGWD reduces inflammatory responses in PTX-treated rats**

Inflammation response has been regarded as an important trigger of CIPN. In this study, serum IL-1\(\beta\), IL-6, and TNF-\(\alpha\) levels were significantly upregulated after PTX administration (IL-1\(\beta\) and IL-6, \(P < 0.05\); TNF-\(\alpha\), \(P < 0.01\)), but this increase was markedly inhibited in both groups treated with high- and low-dose HGWD (Fig. 5a-c). IL-10, an active anti-inflammatory cytokine that suppresses pro-inflammatory signals, was found to be increased in HGWD-treated rats, suggesting the anti-inflammatory effect of HGWD (Fig. 5d). A similar pattern was observed for IL-1\(\beta\), IL-6, TNF-\(\alpha\), and IL-10 mRNA in rat DRG (Fig. 5e-h). These data suggest that HGWD could markedly inhibit the inflammatory response evoked by PTX.

**HGWD inhibits oxidative stress in PTX-treated rats**

Excessive oxidative stress has been found to be involved in the development of CIPN. The levels of oxidative stress parameters (SOD, MDA, 8-isoprostane F2\(\alpha\), and ROS) were detected in this work. Compared with the vehicle group, the serum of PTX-treated rats showed increased MDA of and decreased SOD (Fig. 6a-c). HGWD dramatically reduced the elevated levels of MDA and promote SOD activity \((P < 0.05\) or \(P < 0.01\)). In the HGWD (20 g/kg)-treated group, elevated 8-isoprostane F2\(\alpha\) level was obviously reduced (from 15.7 ± 5.7 ng/ml to 12.7 ± 3.4 ng/ml). To further elucidate the antioxidative effect of HGWD, ROS level in DRG was also measured (Fig. 6d). The results revealed that PTX increased ROS generation in DRG neurons, whereas HGWD blocked ROS production. These findings indicate that HGWD inhibits oxidative stress and maintains a redox balance in PTX-treated rats.

**Active compounds screening and target prediction of HGWD formula**

In this study, active chemical compounds in HGWD were searched from the TCMSP and TCMID databases, and the ingredients and their physicochemical properties were collected. Next, an ADME system was applied to filter out the potential active compounds of HGWD, which met the standards of \(OB \geq 30\%\), \(DL \geq 0.18\), and \(HL \geq 4\). Finally, a total of 30 active chemical ingredients were obtained from HGWD (Table 1). These active compounds mainly belonged to phenols, flavonoids, and lignans. To elucidate the action mechanism of HGWD, the possible targets of its active compounds were clarified by using SMILES to net the targets in the TargetNet database and literature mining. The main targets of PIPN-related diseases were obtained from several databases, including OMIM, NCBI-gene, GeneCards, and DisGENET. By mapping the prediction targets of HGWD with PIPN-related disease targets, 158 potential common targets were obtained and displayed in the overlapping part from the Venn diagram and the interactive network (Fig. 7a).

**GO, KEGG, and target proteins distribution enrichment analyses**
After identifying the potential common targets of HGWD and PIPN, GO and KEGG enrichment analyses were conducted to explore the action mechanism of HGWD. As shown in Fig. 7b & c, the biological processes, cellular component, and molecular function categories in GO enrichment \((P < 0.05)\) and the signal pathways in KEGG enrichment \((P < 0.05)\) were screened and visualised. GO enrichment results showed that the targets of HGWD involved 10 significant terms in biological processes, cellular components, and molecular functions. Among them, the closely related biological processes included RNA biosynthetic process, positive regulation of gene expression, and nucleic acid-templated transcription. KEGG enrichment analysis showed that 25 pathways were involved in the protective effect of HGWD against PIPN. The top 3 pathways ranked by \(-\log(p\text{-value})\) were as follows: the PI3K-Akt, Toll-like receptor, and HIF-1 signalling pathway. Enrichment analysis of 158 potential common target proteins showed that the cell and tissue distribution of the potential target proteins mainly included the liver, smooth muscle, spleen, and DRG (Supplementary Figure S1).

**PPI network analysis**

PPI network was built to analyse the complex interactome organisation between potential common targets. As shown in Fig. 8a, the thickness of the line reflects the magnitude of betweenness centrality, whereas the size with the colour of the nodes represents the degree value. Commonly, proteins with a high degree are considered hubs, which should be focused on and regarded as core targets in network analysis. The results revealed that the degree values of STAT3, AKT1, TP53, MAPK1, JUN, RELA, TNF, and MAPK8 were greater than triple the average degree value (average degree = 7.19). These targets with a high degree value played an important role in the PPI network and may be of great significance in the treatment of PIPN by HGWD.

**C-T and T-P network analysis**

The C-T network diagram was constructed based on 188 nodes (30 potential compounds and 158 potential targets) and 535 edges (Fig. 8b). Quercetin is the pivotal compound of HGWD, showing the highest number of target interactions (degree = 69), followed by kaempferol (degree = 45), formononetin (degree = 38), isorhamnetin (degree = 31), cinnamaldehyde (degree = 25), and cinnamic acid (degree = 23). In addition, the high-degree targets were related to multiple compounds, such as PTGS1 (degree = 20), RELA (degree = 19), PTGS2 (degree = 17), ESR1 (degree = 16), ABCG2 (degree = 13), NFE2L2 (degree = 12), and TLR4 (degree = 12). The T-P network consisting of 71 targets and 15 enriched pathways is shown in Fig. 8c. Many pathways are regulated by multiple target proteins, as might be the crucial pharmacological mechanism of HGWD against PIPN. The key signalling pathways included the PI3K/AKT (degree = 25), MAPK (degree = 21), NOD-like receptor (degree = 19), and Toll-like receptor (degree = 17) signalling pathway. These high-degree targets and pathways might be the major mediators of the neuroprotective effect of HGWD against PIPN.

**HGWD downregulates TLR4/NF-κB signalling and activates PI3K/Akt-Nrf2 pathway in PTX-treated rats**
To validate the results of the network pharmacology analysis and elucidate the mechanisms underlying the neuroprotective effect of HGWD, the expression of key proteins related with TLR4/NF-κB and PI3K/Akt-Nrf2 signalling pathways in DRG were validated by western blotting analysis. It was found that the expression of TLR4 and its adaptor protein MyD88 significantly increased after PTX treatment (Fig. 9a). As TLR4/MyD88 pathway activates downstream effector NF-κB and accelerates pro-inflammatory responses, NF-κB and its core regulator IKKα were also analysed. As presented in Fig. 9a, p-NF-κB and IKKα was significantly elevated in the DRGs of PTX-treated rats. HGWD dramatically decreased TLR4, MyD88, IKKα, and p-NF-κB expression, indicating that HGWD suppressed the PTX-induced activation of TLR4/NF-κB signalling.

PI3K/Akt-Nrf2 pathway is a classical pathway regulating antioxidative stress. In this study, the activation of the PI3K/Akt pathway and the expression of Nrf2 after HGWD treatment were further evaluated to better understand how HGWD exerts protective effect against PIPN. As shown in Fig. 9b, the levels of PI3K protein and phosphorylated Akt in the DRG of PIPN rats were decreased compared with those in the vehicle group. Treatment of PIPN rats with 10 and 20 mg/kg HGWD increased PI3K protein levels and the downstream p-Akt/Akt ratio. The antioxidant transcription factor Nrf2 plays a pivotal role in defensive responses against oxidative stress. In our study, we found that the expression of Nrf2 and HO-1 was significantly elevated in the DRGs of the PIPN model group (Fig. 9c), suggesting the activation of the endogenous antioxidative defence response in PIPN rats. HGWD treatment further promoted the expression of Nrf2 and HO-1. These results suggest that HGWD may play an oxidative stress role by activating the PI3K/Akt-Nrf2 pathway.

HGWD did not compromise the antitumor effect of PTX in cancer cells and mouse xenograft models

After evaluating the neuroprotective effects of HGWD, we further investigated its effect on the chemotherapeutic activity of PTX. As shown in Fig. 10a & b, PTX suppressed the growth of MDA-MB-231 breast cancer cells and CFPAC-1 pancreatic cancer cells by 42.5 ± 3.3% and 36.8 ± 8.3%, respectively (P< 0.001). PTX-induced decreases in MDA-MB-231 and CFPAC-1 cell viability were significantly potentiated after co-incubation with HGWD (Fig. 10a & b). In a xenograft mouse model implanted with CFPAC-1 cells, tumour growth was significantly inhibited by PTX compared with that in the vehicle controls (P< 0.01) (Fig. 10c & d). Combinatorial use of PTX and HGWD led to little compromise on tumour growth inhibition of PTX. Both the in vitro and in vivo studies indicate that HGWD does not compromise the antitumor activity of PTX.

Discussion

In this study, we revealed that HGWD significantly ameliorated PIPN and did not compromise the tumour cell-killing ability of PTX. To elucidate the underlying mechanism of HGWD against PIPN, network pharmacology was performed to analyse its potential active components and targets. The results of bioinformatics predictions and experimental validation showed that HGWD inhibited TLR4/NF-κB
signalling and activated PI3K/Akt/Nrf2 pathways in PIPN rats. To our knowledge, this is the first study to elucidate the effect and protective mechanism of HGWD on PTX-induced neurotoxicity in vivo.

PIPN remains a difficult and unmet clinical problem. Herbal formula HGWD has been used to treat numbness, vibration sensation, cold sensation, and limb ache since the Eastern Han Dynasty, which is considered a potential complementary therapy providing neuronal protection in chemotherapy [16]. Recently, HGWD has been proven to be effective in treating oxaliplatin- and diabetic peripheral neuropathy in animal models and clinical studies [12, 13]. However, the effect of HGWD on PIPN with its pharmacological mechanism remains unclear. Thus, in this study, we tested whether HGWD alleviates PIPN and explore the underlying pharmacological mechanism.

A rat experimental model of PIPN was established and used because rats are physiologically closer to humans than mice [17]. HGWD effectively attenuated the mechanical allodynia and thermal hyperalgesia evoked by PTX (Fig. 2b & c). Moreover, pre-treatment with HGWD significantly rescued PTX-induced morphometric changes in peripheral sensory neurons, such as shrinkage of DRG nucleoli, axonal degeneration, and myelin damage in the sciatic nerve (Fig. 2c & Fig. 3). Furthermore, PTX damaged IENFs and led to IENF loss, which was primarily responsible for neuropathic pain [18]. As shown in Fig. 4a & b, HGWD remarkably attenuated this neurotoxic effect evidenced by increasing the density of PGP9.5. NGF is a well-known indicator for predicting the clinical severity and outcome of neuropathy in patients with CIPN. We found that HGWD treatment notably elevated serum NGF levels in PIPN rats. These results suggest that HGWD could effectively attenuates PIPN.

Increasing evidence has shown that inflammation is critical in the development of CIPN [19]. Excessive secretion of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, enhances PTX-induced peripheral sensitisation of sensory neurons and mechanical allodynia [20]. In this work, the modulation of HGWD on inflammatory cytokines was examined. Here, increases in IL-1β, IL-6, and TNF-α levels were observed in rat serum and DRG after PTX injection (Fig. 5). Interestingly, HGWD reversed the elevation of pro-inflammatory cytokines and increased IL-10, suggesting that its neuroprotection against PIPN is mediated, at least in part, by an anti-inflammatory activity (Fig. 5). In addition to inflammation, oxidative stress, which is caused an imbalance between free radicals and antioxidant defences, has been identified to be closely associated with CIPN pathogenesis [21]. ROS scavengers, such as phenyl-N-tert-butyl nitrite and acetyl-L-carnitine, have been shown to prevent and reverse PTX-induced pain [22]. In our experiment, SOD, MDA, and 8-isoprostane F2α levels were measured as markers of oxidative stress. As shown in Fig. 6, increased MDA and 8-isoprostane F2α levels and decreased SOD activity were observed in PIPN rodent models. PTX-induced elevation of oxidative stress was attenuated by HGWD. In addition, the PTX-induced increase in ROS generation in DRG was blocked by HGWD, suggesting that HGWD exerted antioxidant effect under PIPN conditions.

Next, network pharmacology was applied to elucidate the action mechanisms of HGWD. Finally, 30 active chemical ingredients with their physicochemical properties were screened from HGWD: 15 compounds from AR, 5 compounds from CR, 3 compounds from PRA, 11 compounds from JF, and 7 compounds
from ZR (Table 1). Most of these active compounds have been reported to exert anti-inflammatory and antioxidant activities, indicating that these compounds may be key constituents for PIPN treatment. For instance, paenoniflorin exerts neuroprotective effect by attenuating oxidative stress through Nrf2 activation in diabetic peripheral neuropathy mice [23]. 6-Gingerol, cinnamic acid, and formononetin have been shown to play antioxidant and anti-inflammatory roles in several neurological diseases, such as ischemic brain damage, Alzheimer’s disease, and oxaliplatin-induced peripheral neuropathy [24–26]. Both KEGG pathway enrichment and network analyses predicted the PI3K-Akt and Toll-like receptor pathways as the key signalling pathways that mediate the protective effect of HGWD against PIPN (Fig. 7 and Supplementary Figure S2). To confirm the prediction, the effect of HGWD on the key proteins in these pathways was evaluated by western blotting. The results showed that HGWD significantly inhibited PTX-induced activation of the inflammatory signalling pathway TLR4/NF-κB and promoted the activation of PI3K/Akt-Nrf2 signalling in the DRG (Fig. 8).

TLR4 protein is a type of immune receptor expressed on cell surfaces and triggers innate immunity. Recently, TLR4 was shown to be involved in PTX-induced neuropathic pain. TLR4 deficiency or pharmacological blocking plays a neuroprotective role in PIPN [27, 28]. In our study, we showed that TLR4/NF-κB signalling pathway was activated in PIPN rats. HGWD treatment significantly inhibited TLR4 and MyD88 activation. Furthermore, HGWD decreased the expression of IKKα, and p-NF-κB (Fig. 9a). Thus, HGWD may play an important role in preventing PIPN by suppressing the activation of the TLR4/NF-κB signalling pathway. Nrf2 is a crucial regulator of defence against oxidative stress. Modulation of Nrf2 may alleviate oxidative stress injury in PIPN (Singh et al., 2019) [29]. Notably, increasing evidence has suggested that PI3K/Akt is upstream of Nrf2 [30, 31]. Nrf2-mediated gene expression correlates with the activation of the PI3K/Akt pathway. As shown in Fig. 9b-c, our results suggest that HGWD attenuated PTX-induced oxidative stress partially by promoting PI3K/Akt-Nrf2 signalling.

Alongside the potential therapeutic effect of HGWD against PIPN, it is critical to determine whether HGWD interferes with the tumour cell-killing effect of chemotherapy. After confirming the neuroprotective action of HGWD against PIPN, we tested the effect of HGWD on the in vitro and in vivo anti-tumour efficacy of PTX. As expected, HGWD did not impair the antitumor activity of PTX in cancer cell lines and mice with transplanted xenografts (Fig. 10).

**Conclusion**

In summary, this study shows that HGWD, a representative prescription for treating “blood impediment”, can mitigate PTX-related neurotoxicity without compromise on antitumor activity of PTX. Network pharmacology combined with subsequent experimental validation suggested that HGWD exerted neuroprotective effect against PIPN partly by inhibiting inflammatory responses and activating antioxidant functions via regulating TLR4/NF-κB and PI3K/Akt-Nrf2 pathways (Fig. 11). This study provides a novel understanding of the classical herbal formula HGWD in the treatment of PIPN. More
experiments are needed to study the in-depth mechanisms of HGWD on paclitaxel-related neurotoxicity in our future work.

**Abbreviations**

PIPN: Paclitaxel-induced peripheral neuropathy; HGWD: Huangqi Guizhi Wuwu decoction; CIPN: chemotherapy-induced peripheral neuropathy; PTX: Paclitaxel; IENFs: intraepidermal nerve fibres; TRP: transient receptor potential channel; MAPK: mitogen-activated protein kinase; ROS: reactive oxygen species; AR: Astragali Radix ; CR: Cinnamomi Ramulus; PRA: Paeonia Radix Alba; JF: Jujubae Fructus; ZR: Zingiberis Rhizoma; ADME: absorption, distribution, metabolism, and excretion; OB: oral bioavailability; C-T: compound-target; T-P: target-pathway.

**Declarations**

**Acknowledgements**

None.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was granted by Project of the Major National Science and Technology Program of China for Innovative Drug (2019ZX09301-145), the National Natural Science Foundation of China (No.81774283), and Key R&D Program of Jiangsu Province (BE2018756), the Open Project of Chinese Materia Medica First-Class Discipline of Nanjing University of Chinese Medicine (No. 2020YLXK003).

**Availability of data and materials**

The datasets used in the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The animal care and experimental procedures used in this study were approved by the Institutional Animal Care and Use Committee of Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine.

**Consent for publication**

Not applicable.
Authors’ contributions

Xiaolan Cheng and Peng Cao conceived and designed this research. Zhangming Lv, Jiayun Shen and Xuejiao Gao carried out the experiments. Xiaolan Cheng and Zhangming Lv wrote the manuscript. Yonglan Ruan, Jingying Ling and Rongwei Sun participated part of the experiments. Jingya Dai and Haizhen Fan performed part of the characterizations. Xiaolan Cheng and Peng Cao revised the manuscript. All the authors have read and approved the final manuscript.

Author details

1 Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China. 2 College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210029, China

References

1. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017;81(6):772–81.

2. Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms. Curr Neuropharmacol. 2019;17(2):184–96.

3. Anoushirvani AA, Poorsaadat L, Aghabozorgi R, Kasravi M. Comparison of the Effects of Omega 3 and Vitamin E on Palcitaxel-Induced Peripheral Neuropathy. Open Access Maced J Med Sci. 2018;6(10):1857–61.

4. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstreip S, Wagner-Johnston N, Bak K, Loprinzi CL. American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.

5. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67.

6. Lees JG, Makker PG, Tonkin RS, et al. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur J Cancer. 2017;73:22–9.

7. Duggett NA, Griffiths LA, McKenna OE, et al. Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy. Neuroscience. 2016;333:13–26.

8. Mallet ML, Hadjivassiliou M, Sarrigiannis PG, Zis P. The Role of Oxidative Stress in Peripheral Neuropathy. J Mol Neurosci. 2020;70(7):1009–17.

9. Sun H, Guo X, Wang Z, et al. Alphalipoic Acid Prevents Oxidative Stress and Peripheral Neuropathy in Nab-Paclitaxel-Treated Rats through the Nrf2 Signalling Pathway. Oxid Med Cell Longev.
10. Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3–9.

11. Zhang H, Li Y, de Carvalho-Barbosa M, et al. Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. J Pain. 2016;17(7):775–86.

12. Zhang Y, Gong G, Zhang X, Zhou L, Xie H, Tian Y, Xie C. Huangqi Guizhi Wuwu decoction for diabetic peripheral neuropathy: Protocol for a systematic review. Med (Baltim). 2019;98(31):e16696.

13. Cheng X, Huo J, Wang D, et al. Herbal Medicine AC591 Prevents Oxaliplatin-Induced Peripheral Neuropathy in Animal Model and Cancer Patients. Front Pharmacol. 2017;8:344.

14. Ba X, Wang J, Zhou S, et al. Cinobufacini protects against paclitaxel-induced peripheral neuropathic pain and suppresses TRPV1 up-regulation and spinal astrocyte activation in rats. Biomed Pharmacother. 2018;108:76–84.

15. Youk J, Kim YS, Lim JA, et al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. PLoS One. 2017;12(8):e0183491.

16. Bai Q. The influence of Huangqi Guizhi Wuwu Decoction on diabetic peripheral neuropathy and nerve conduction velocity. Chinese Traditional Patent Medicine. 2015;37(5):962–4.

17. Currie GL, Angel-Scott HN, Colvin L, et al. Animal models of chemotherapy-induced peripheral neuropathy: A machine-assisted systematic review and meta-analysis. PLoS Biol. 2019;17(5):e3000243.

18. Mangus LM, Rao DB, Ebenezer GJ. Intraepidermal Nerve Fiber Analysis in Human Patients and Animal Models of Peripheral Neuropathy: A Comparative Review. Toxicol Pathol. 2020;48(1):59–70.

19. Montague K, Malcangio M. The Therapeutic Potential of Monocyte/Macrophage Manipulation in the Treatment of Chemotherapy-Induced Painful Neuropathy. Front Mol Neurosci. 2017;10:397.

20. Deuis JR, Yin K, Cooper MA, Schroder K, Vetter I. Role of the NLRP3 inflammasome in a model of acute burn-induced pain. Burns. 2017;43(2):304–9.

21. Areti A, Yerra VG, Naidu V, Kumar A. Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol. 2014;2:289–95.

22. Xiao WH, Bennett GJ. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain. 2012;153(3):704–9.

23. Yang X, Yao W, Shi H, et al. Paeoniflorin protects Schwann cells against high glucose induced oxidative injury by activating Nrf2/ARE pathway and inhibiting apoptosis. J Ethnopharmacol. 2016;185:361–9.

24. Liu Y, Deng S, Zhang Z, et al. 6-Gingerol attenuates microglia-mediated neuroinflammation and ischemic brain injuries through Akt-mTOR-STAT3 signaling pathway. Eur J Pharmacol. 2020;883:173294.

25. Chainoglou E, Siskos A, Pontiki E, Hadjipavlou-Litina D. Hybridization of Curcumin Analogues with Cinnamic Acid Derivatives as Multi-Target Agents Against Alzheimer's Disease Targets. Molecules.
26. Fang Y, Ye J, Zhao B, et al. Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis. Redox Biol. 2020;36:101677.
27. Li Y, Adamek P, Zhang H, et al. The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4. J Neurosci. 2015;35(39):13487–500.
28. Li Y, Zhang H, Zhang H, Kosturakis AK, Jawad AB, Dougherty PM. Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. J Pain. 2014;15(7):712–25.
29. Singh J, Saha L, Singh N, Kumari P, Bhatia A, Chakrabarti A. Study of nuclear factor-2 erythroid related factor-2 activator, berberine, in paclitaxel induced peripheral neuropathy pain model in rats. J Pharm Pharmacol. 2019;71(5):797–805.
30. Zhang J, Tong W, Sun H, et al. Nrf2-mediated neuroprotection by MANF against 6-OHDA-induced cell damage via PI3K/AKT/GSK3β pathway. Exp Gerontol. 2017;100:77–86.
31. Lai TT, Yang CM, Yang CH. Astaxanthin Protects Retinal Photoreceptor Cells against High Glucose-Induced Oxidative Stress by Induction of Antioxidant Enzymes via the PI3K/Akt/Nrf2 Pathway. Antioxidants (Basel). 2020;9(8):729.

Tables

Due to technical limitations, table 1 is only available as a download in the Supplemental Files section.

Figures
Figure 1

The research framework of this study
Figure 2

HGWD attenuated mechanical allodynia, thermal hyperalgesia, and morphological changes of DRG in PIPN rats. (a) Protocol showing drug administration and behavioral tests in the rat model. (b) Mechanical withdrawal threshold was measured by the von Frey test. (c) Thermal withdrawal threshold was evaluated by the hot plate test. (d) Time course effect of HGWD on body weight of rats. (e) DRG sections were stained by Nissl and observed by light micrographs (80×). The occurrence of eccentric nucleoli (red...
arrow) and multinucleolated neurons (red arrowhead) were analyzed. Histograms show the effect of HGWD on the incidence of nuclear and nucleolar pathological features. *P < 0.05, **P < 0.01 ***P < 0.001, vs. vehicle group; #P < 0.05, ##P < 0.01, ###P < 0.001, vs. PIPN group, n = 8 rats/group.

Figure 3

HGWD attenuated paclitaxel induced histological changes in sciatic nerves. (a) Cross view of ultrastructure of rat sciatic nerve. Scale bar, 5 μm. (b) Paclitaxel-induced sciatic nerve damage includes axonal degeneration and myelin damage. Scale bar, 2 μm. (c) Representative transmission electron microscopy images show that paclitaxel caused swollen and vacuolated mitochondria (red arrow). Scale bar, 1 μm. (d) G-ratio (the ratio of inner axon circumference to outer myelin circumference) measurement in the sciatic nerves. Each value represents mean ± SEM of at least 32 sciatic nerves. **P < 0.01, ****P < 0.0001, vs. vehicle group; #P < 0.05, ####P < 0.0001, vs. PIPN group.
Figure 4

HGWD attenuated paclitaxel induced histological changes in sciatic nerves. (a) Cross view of ultrastructure of rat sciatic nerve. Scale bar, 5 μm. (b) Paclitaxel-induced sciatic nerve damage includes axonal degeneration and myelin damage. Scale bar, 2 μm. (c) Representative transmission electron microscopy images show that paclitaxel caused swollen and vacuolated mitochondria (red arrow). Scale bar, 1 μm. (d) G-ratio (the ratio of inner axon circumference to outer myelin circumference) measurement in the sciatic nerves. Each value represents mean ± SEM of at least 32 sciatic nerves. **P < 0.01, ****P < 0.0001, vs. vehicle group; #P < 0.05, ####P < 0.0001, vs. PIPN group.
Figure 5

HGWD alleviated paclitaxel induced inflammation responses. (a-d) Protein expression of proinflammatory cytokines in serum were determined by ELISA. (e-h) mRNA expression of proinflammatory cytokines in DRG neurons were detected by RT-PCR. **P < 0.01 vs. vehicle, ##P < 0.01 vs. PIPN alone.
Figure 6

HGWD reduced oxidative stress in PTX-treated rats. (a) SOD activity. (b) MDA content. (c) 8-isoprostane F2α level. (d) ROS production detected with immunofluorescence in DRG. Results are the mean ± SEM from three independent experiments. *P < 0.05, ***P < 0.001 vs. vehicle group, #P < 0.05, ##P < 0.01 vs. PIPN group.
Figure 7

Target prediction of HGWD with GO and KEGG enrichment analysis. (a) The Venn diagram of disease targets and HGWD targets showed 158 key target proteins in the overlapping part, and the schematic diagram was displayed. (b) The top 10 significant terms respectively in GO biological process, cellular component and molecular function classification, and the order of importance was ranked from left to right by -log(p-value). (c) The top 25 significant terms in KEGG pathways enrichment. The molecule
number of target genes enriched in the KEGG pathway was showed, and the order of importance was ranked from top to bottom by -log(p-value).

**Figure 8**

Network analysis. (a) Protein-protein interaction network analysis. The thickness of the line reflects the magnitude of Betweenness Centrality, and the color and depth of the nodes (blue→yellow→red) represent the size of the degree value (high→low). (b) Compound-Target network analysis. The navy-blue squares represent the compounds, and diverse colors of circles represent the target proteins distributed in various areas of the cell, such as extracellular region, plasma membrane, cytosol, endoplasmic reticulum, mitochondrion, and nucleus. (c) Target-Pathway network analysis. The navy-blue squares represent the pathways which were the top 15 significant changes in KEGG enrichment.
HGWD regulated the expression of TLR4/NF-κB and PI3K/Akt-Nrf2 pathways in PTX-treated rats. (a) HGWD downregulated TLR4/NF-κB signaling. (b) HGWD upregulated the expression of PI3K and phosphorylated Akt proteins. (c) HGWD activated Nrf2-OH-1 pathway. Levels of TLR4, MyD88, IKKa, NF-κB, p-NF-κB, PI3K, p-AKT, Nrf2, Keap1, HO-1, and β-tubulin from DRG tissues were determined by western
blot analysis. Data are expressed as means ± SEM. *P < 0.05, **P < 0.01 ***P < 0.001, vs. vehicle group; 
# P < 0.05, ## P < 0.01, ### P < 0.001, vs. PIPN group.

Figure 10

Evaluation of potential effects of HGWD on paclitaxel efficacy in tumor cell lines and a tumor growth model. (a-b) Tumor cell survival as measured by MTT assay in MDA-MB-231 breast cancer cells (a), and CFPAC-1 pancreatic cancer cells (b) (24h). (c-d) Tumor size in nude BALB/c mice injected subcutaneously into the right flank with 4×10^6 CFPAC-1 cells and treated with vehicle, paclitaxel (i.p., 10 mg/kg), paclitaxel associated with HGWD (i.g., 30 g/kg). **P < 0.01, ***P < 0.001 vs. vehicle.
Figure 11

The connection between pathways and the key targets of HGWD acting on PIPN. Most of the targets have been validated.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• Table1.docx
• Supplementarymaterials.docx